Resistance to Targeted Therapies in Melanoma – New Insights

Giuseppe Palmieri,1 Maria Colombino,1 Maria Cristina Sini,1 Antonella Manca,1 Paolo Antonio Ascierto,2 Antonio Cossu3

1. Institute of Biomolecular Chemistry, National Research Council, Region Baldinca, Sassari, Italy
2. National Cancer Institute “G. Pascale” Foundation, Napoli, Italy
3. University Hospital, Sassari, Italy

Disclosure: Paolo Antonio Ascierto is a consultant of Bristol Myers Squibb, MSD, and Roche-Genentech. He participated in the Advisory Board from Bristol Myers Squibb, MSD, Roche-Genentech, GSK, Amgen, Celgene, Medimmune, and Novartis. He received honoraria from Brystol Myers Squibb, MSD, and Roche-Genentech. All remaining authors declare the absence of any conflict of interest.
Received: 18.10.13 Accepted: 19.11.13
Citation: EMJ Dermatol. 2013;1:24-37.

Abstract

Several molecular mechanisms are involved in melanoma genesis and progression. Molecular targets for effective therapeutic intervention have been identified within the RAS-RAF-MEK-ERK and, to a less extent, PI3K-AKT pathways. The development of inhibitors of key effectors (mainly BRAF mutant, MEK, and KIT) into such pathways has significantly improved the treatment of patients with advanced melanoma. However, emerging data indicate that a large variety of acquired and intrinsic mechanisms may drive resistance to the main targeted inhibitors. All the evidence suggests that in melanoma, as probably in all types of cancer, it is unlikely that targeting a single component in pathogenetic signaling pathways could yield significant antitumour responses. Therefore, knowledge of the multiple altered signalling events involved in response and resistance to targeted treatments will allow for the development of more effective combination therapies, which may represent the next challenge for the management of patients with such a disease.

Download (PDF, 169KB)

Leave a Reply